UGT1A1 and colorectal cancer: Furthermore, meta-data-based pharmacogenetic study of colorectal cancer patients established strong associations between germline variants of UGT1 and clinical outcomes, and have strongly supported the role of the UGT1A enzyme pathway in mediating the response to SN-38 [89,90].